Owners, management and financials
CVR: 39359340
DKK 1,441,140
Gross profit
Net result: DKK 115,004
Amicus Therapeutics UK Ltd. (100%)
CVR · view owners
Richard Gideon Morris
Board: Richard Gideon Morris (chair) and 2 members
CVR · view management
Active
Founded 23 February 2018
CVR · view overview
1 employee
CVR · 2026
Director role ended: Ana Rogovic
CVR · 17/06/2026
View the full event history
Amicus Therapeutics ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Richard Gideon Morris. The board consists of Richard Gideon Morris (chair), Brian Keogh and Graham Stewart Riley Morris. The company is owned by Amicus Therapeutics UK Ltd.. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 1,441,140 and a net result of DKK 115,004 compared with DKK 16,475 the year before. Equity in the 2025 report amounted to DKK 424,641.
Source: annual report 2025, Danish Business Authority
Amicus Therapeutics ApS demonstrates a positive trend in gross profit and profitability over the past few years, with gross profits increasing from 644,168 DKK in 2021 to 1,441,140 DKK in 2025. The company has maintained profitability, with profits rising from 19,351 DKK in 2021 to 115,004 DKK in 2025, indicating effective cost management and operational efficiency. Equity has also grown significantly, reaching 424,641 DKK in 2025, which strengthens its financial position. However, the lack of disclosed revenue figures may raise concerns about transparency and market position within the pharmaceutical wholesale industry. Overall, the company appears to be on a solid growth trajectory, bolstered by improving margins and equity.
AI-generated summary · Generated 13/08/2026
Selskabets formål er at markedsføre, distribuere og sælge produkter og tjenesteydelser.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 1.4M | 115K | 4.2M | 425K | 1 | |
| 202401/01/2024 – 31/12/2024 | 2M | 16K | 3.4M | 310K | 1 | |
| 202301/01/2023 – 31/12/2023 | 1.7M | 52K | 734K | 355K | 1 | |
| 202201/01/2022 – 31/12/2022 | 1.6M | 54K | 617K | 303K | 1 | |
| 202101/01/2021 – 31/12/2021 | 644K | 19K | 2.4M | 249K | 1 | |
| 202001/01/2020 – 31/12/2020 | 490K | 22K | 2.3M | 230K | 1 | |
| 201901/01/2019 – 31/12/2019 | 2M | 84K | 497K | 208K | 2 | |
| 201823/02/2018 – 31/12/2018 | 2M | 74K | 2M | 124K | 2 |
Compared to 405 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorThe CVR number of Amicus Therapeutics ApS is 39359340.
Amicus Therapeutics ApS is owned by Amicus Therapeutics UK Ltd..
The management of Amicus Therapeutics ApS consists of Richard Gideon Morris.
The board of Amicus Therapeutics ApS consists of Richard Gideon Morris, Brian Keogh and Graham Stewart Riley Morris, with Richard Gideon Morris as chair.
In 2025, Amicus Therapeutics ApS reported a gross profit of DKK 1,441,140.
Amicus Therapeutics ApS had 1 employee in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
As of October 7, 2026, Graham Stewart Riley Morris has joined the board of directors of Amicus Therapeutics ApS.
As of October 7, 2026, Steven John Green has left the board of directors of Amicus Therapeutics ApS.
Amicus Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK 1,441,140, and the net result was DKK 115,004.
As of June 17, 2026, Brian Keogh has joined the board of directors of Amicus Therapeutics ApS.
As of June 17, 2026, Richard Gideon Morris has joined the board of directors of Amicus Therapeutics ApS.
As of June 17, 2026, Ana Rogovic has left the board of directors of Amicus Therapeutics ApS.
As of June 17, 2026, Jessica Alice Stephens-Brown has left the board of directors of Amicus Therapeutics ApS.
As of June 17, 2026, Richard Gideon Morris is registered as director of Amicus Therapeutics ApS.
As of June 17, 2026, Ana Rogovic has stepped down as director of Amicus Therapeutics ApS.
Amicus Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK 1,987,087, and the net result was DKK 16,475.
As of October 7, 2024, Ana Rogovic has joined the board of directors of Amicus Therapeutics ApS.
As of October 7, 2024, Jessica Alice Stephens-Brown has joined the board of directors of Amicus Therapeutics ApS.
As of October 7, 2024, Charlotte Ann Galvin has left the board of directors of Amicus Therapeutics ApS.
As of October 7, 2024, David Malcolm Lewis has left the board of directors of Amicus Therapeutics ApS.
As of October 7, 2024, Ana Rogovic is registered as director of Amicus Therapeutics ApS.
As of October 7, 2024, Charlotte Ann Galvin has stepped down as director of Amicus Therapeutics ApS.
Amicus Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK 1,732,212, and the net result was DKK 52,221.
As of February 1, 2024, David Malcolm Lewis has joined the board of directors of Amicus Therapeutics ApS.
As of January 31, 2024, Anita Jane Clifford has left the board of directors of Amicus Therapeutics ApS.
Amicus Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK 1,575,511, and the net result was DKK 54,033.
As of May 24, 2023, Charlotte Ann Galvin has joined the board of directors of Amicus Therapeutics ApS.
As of May 24, 2023, Charlotte Ann Galvin is registered as director of Amicus Therapeutics ApS.
As of March 17, 2023, John Erik Mattias Bankel has left the board of directors of Amicus Therapeutics ApS.
As of March 17, 2023, John Erik Mattias Bankel has stepped down as director of Amicus Therapeutics ApS.
Amicus Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK 644,168, and the net result was DKK 19,351.
Amicus Therapeutics ApS has published its annual report for 2020. Gross profit came to DKK 490,223, and the net result was DKK 21,886.
As of May 3, 2021, Steven John Green has joined the board of directors of Amicus Therapeutics ApS.
As of May 3, 2021, Nicole Ruth Reichman has left the board of directors of Amicus Therapeutics ApS.
Amicus Therapeutics ApS has published its annual report for 2019. Gross profit came to DKK 2,019,085, and the net result was DKK 84,291.
As of February 28, 2020, Nicole Ruth Reichman has joined the board of directors of Amicus Therapeutics ApS.
As of February 28, 2020, Anita Jane Clifford has joined the board of directors of Amicus Therapeutics ApS.
As of February 28, 2020, John Erik Mattias Bankel has joined the board of directors of Amicus Therapeutics ApS.
As of February 28, 2020, Johnny Krogh Hansen has left the board of directors of Amicus Therapeutics ApS.
As of February 28, 2020, Simon Collins has left the board of directors of Amicus Therapeutics ApS.
As of February 28, 2020, Lori Mochan has left the board of directors of Amicus Therapeutics ApS.
As of February 28, 2020, John Erik Mattias Bankel is registered as director of Amicus Therapeutics ApS.
As of February 28, 2020, Johnny Krogh Hansen has stepped down as director of Amicus Therapeutics ApS.
Amicus Therapeutics ApS has published its interim report for the period February 23, 2018 to December 31, 2018.
As of February 12, 2019, Detlef Wolff has left the board of directors of Amicus Therapeutics ApS.
As of July 6, 2018, Lori Mochan has joined the board of directors of Amicus Therapeutics ApS.
As of July 6, 2018, Detlef Wolff has joined the board of directors of Amicus Therapeutics ApS.
As of July 6, 2018, Jasvinder Sarkaria has left the board of directors of Amicus Therapeutics ApS.
As of February 23, 2018, Johnny Krogh Hansen has joined the board of directors of Amicus Therapeutics ApS.
As of February 23, 2018, Jasvinder Sarkaria has joined the board of directors of Amicus Therapeutics ApS.
As of February 23, 2018, Simon Collins has joined the board of directors of Amicus Therapeutics ApS.
As of February 23, 2018, Johnny Krogh Hansen is registered as director of Amicus Therapeutics ApS.
As of February 23, 2018, is registered as an owner of Amicus Therapeutics ApS with an ownership share of 100%.
Amicus Therapeutics ApS was founded on February 23, 2018.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Companies in the same industry and area
CVR 37626619
CVR 41183144
CVR 35451307
CVR 36392398
CVR 14479880
